Callan Family Office’s BioMarin Pharmaceuticals BMRN Stock Holding History

Callan Family Office’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-6,754	Closed	-$401K	–	1138
2025 Q4	$401K	Sell	6,754 -35,137	-84%	-$1.91M	0.01%	843
2025 Q3	$2.27M	Sell	41,891 -25,147	-38%	-$1.44M	0.07%	248
2025 Q2	$3.69M	Buy	67,038 +47,264	+239%	+$2.78M	0.12%	191
2025 Q1	$1.4M	Buy	19,774 +12,304	+165%	+$828K	0.1%	168
2024 Q4	$491K	Buy	+7,470	New	+$500K	0.03%	372
2023 Q2	–	Sell	-5,000	Closed	-$486K	–	114
2023 Q1	$486K	Buy	+5,000	New	+$518K	0.12%	93

Other funds holding BMRN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Callan Family Office's BMRN Position: Q1 2026 in Review

Callan Family Office sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2026, closing a stake of 6,754 shares — an estimated $401K sold.

Callan Family Office first reported a position in BMRN in Q1 2023 and held it in 6 quarters. The position peaked at $3.69M in Q2 2025. 554 funds tracked by Wall St. Rank hold BMRN as of Q1 2026.

Callan Family Office reported no remaining BioMarin Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Callan Family Office sold 6,754 BioMarin Pharmaceuticals shares in Q1 2026, an estimated $401K.
Callan Family Office first reported a position in BioMarin Pharmaceuticals in Q1 2023 and held it in 6 quarters.
Callan Family Office's BioMarin Pharmaceuticals position peaked at $3.69M in Q2 2025.
554 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2026.

Based on Callan Family Office's 13F filing for Q1 2026, filed 13 May 2026.